Clinical bottom line
Biologic therapies have revolutionized the management of moderate-to-severe plaque psoriasis, offering targeted treatment options that can achieve significant skin clearance and improve quality of life. The selection of a biologic agent should be tailored to individual patient needs, considering factors such as efficacy, safety profile, comorbid conditions, and patient preferences. Current evidence supports the use of IL-17 inhibitors, IL-23 inhibitors, and TNF-alpha inhibitors, each with distinct benefits and limitations.
What the evidence shows
A range of biologics is available for the treatment of plaque psoriasis, including tumor necrosis factor (TNF) inhibitors, interleukin-17 (IL-17) inhibitors, and interleukin-23 (IL-23) inhibitors. A systematic review by Sbidian et al. (2021) compared the efficacy and safety of these agents, finding that IL-17 and IL-23 inhibitors generally offer superior efficacy in achieving Psoriasis Area and Severity Index (PASI) 90 responses compared to TNF inhibitors (PMID: 33657292).
IL-17 inhibitors, such as secukinumab and ixekizumab, have demonstrated rapid onset of action and high efficacy in clinical trials. A study by Blauvelt et al. (2017) showed that ixekizumab achieved PASI 90 responses in a significant proportion of patients, with sustained effects over 60 weeks (PMID: 28216610). Similarly, IL-23 inhibitors like guselkumab and risankizumab have shown impressive efficacy, with risankizumab achieving PASI 90 responses in over 70% of patients in pivotal trials (PMID: 30208491).
TNF inhibitors, including adalimumab and etanercept, remain valuable options, particularly for patients with concomitant psoriatic arthritis. However, their efficacy in achieving complete skin clearance may be lower compared to IL-17 and IL-23 inhibitors.
Caveats and uncertainty
While biologics offer substantial benefits, several caveats must be considered. The long-term safety of these agents, particularly regarding infection risk and potential malignancy, requires ongoing monitoring. Additionally, the high cost of biologics may limit accessibility for some patients, necessitating consideration of healthcare resources and insurance coverage.
The variability in patient response to different biologics underscores the need for personalized treatment plans. Factors such as previous treatment history, presence of comorbidities, and patient preferences should guide therapy selection. Furthermore, the emergence of biosimilars offers potential cost savings, but their interchangeability with originator biologics requires careful consideration.
How this may change practice
The updated evidence on biologic selection for plaque psoriasis highlights the importance of a personalized approach to treatment. Clinicians should consider the efficacy and safety profiles of IL-17 and IL-23 inhibitors, particularly for patients seeking rapid and sustained skin clearance. TNF inhibitors remain a valuable option for patients with psoriatic arthritis or specific contraindications to other biologics.
In practice, this may lead to more tailored treatment plans, optimizing outcomes while minimizing side effects. As new evidence emerges, clinicians should remain informed about updates to guidelines and integrate these into their practice to ensure effective management of plaque psoriasis.